ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Study Identifies Risk Factors To Predict Contralateral Cancer

February 27, 2009

Report Questions Effectiveness Of Bimanual Pelvic Exam

March 31, 2006

In Brief: Boutwell Declines Nomination to New NCAB Term; Rowley Again Urges Appointment Of Scientists

January 20, 1984

In Brief: NCI To Move From Westwood, Landow, Blair Bldgs; Kinsella Names UW Oncology Chairman

October 9, 1987

NCAB Hears Good News: FY 92 Budget Allows NCI To Increase Levels Of Most Programs

November 29, 1991

Surveillance Colonoscopy Cost-Effective For High-Risk

July 30, 2010